{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-251264","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.461776+00:00","generated_at":"2026-06-23T07:28:03.392084+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Wave Life Sciences CMO Michael Panzara resigns; Anne-Marie Li-Kwai-Cheung promoted to CDO","bullets":["Michael Panzara, M.D., MPH, resigns as CMO effective Oct 14, 2022, to pursue another opportunity; no disagreement with company.","Dr. Panzara will serve as consultant post-resignation for transition.","Anne-Marie Li-Kwai-Cheung promoted to Chief Development Officer effective Oct 14, 2022.","Li-Kwai-Cheung previously led Roche's tominersen Phase 3 program and Ocrevus global launch.","She brings deep neurology and rare disease drug development experience to Wave."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-251264","json":"https://secwatch.observer/filing/0001193125-22-251264.json","markdown":"https://secwatch.observer/filing/0001193125-22-251264.md","text":"https://secwatch.observer/filing/0001193125-22-251264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/d392497d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:28:03.392084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f4be2a135","claim":"Michael Panzara resigned as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences Ltd..","evidence_excerpt":"On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer, Head of Therapeutics Discovery and Development"}],"fact_type":"executive_change"},{"claim_id":"e79301eb95","claim":"Anne-Marie Li-Kwai-Cheung was appointed as Chief Development Officer at Wave Life Sciences Ltd..","evidence_excerpt":"Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312522251264/0001193125-22-251264-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}